(NYSE American: ATNM) Is Pioneering Targeted Radiotherapy For Oncology (4 Potential Catalysts To Know)

*Sponsored StockWireNews (NYSE American: ATNM) Is Pioneering Targeted Radiotherapy For Oncology (4 Potential Catalysts To Know) March 26th Greetings Readers, It's Wednesday morning and there's zero time to waste. I've been tracking a company that's been on a tear and displaying serious breakout potential. In the last couple weeks, several positive press releases have been shared by this company painting a positive trajectory in 2025 and beyond. But it's not just that... This profile has moved above several key lines of potential chart support. If support starts growing significantly at those levels, it could help this profile gain enough momentum to try and track down previous highs. Another highlight? How about an analyst target pointing to triple-digit potential upside from its closing valuation Tuesday? Listen. There's a lot to go over, so clear your plate and pay close attention. Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is a pioneer in targeted radiotherapy for oncology. The company is advancing Actimab-A, a CD33-targeting therapeutic designed as a backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies. Actimab-A leverages Actinium-225 (Ac-225), a mutation-agnostic alpha-emitter radioisotope, to deliver targeted radiotherapy directly to cancer cells. Key Developments For Actinium Pharmaceuticals Actimab-A has shown high rates of Complete Remission (CR) and measurable residual disease (MRD) negativity in relapsed and refractory AML (r/r AML) patients. The candidate is advancing to a pivotal Phase 2/3 clinical trial, with potential implications for significantly improved patient outcomes. Actinium is working with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) to expand Actimab-A's applications. Beyond AML, Actinium Pharmaceuticals, Inc. is also developing Actimab-A as a combination therapy for solid tumors, particularly in combination with PD-1 checkpoint inhibitors, such as: KEYTRUDA® (Merck & Co.) OPDIVO® (Bristol Myers Squibb) Breakthrough Potential In The Immuno-Oncology Market Actinium Pharmaceuticals, Inc. recently announced a clinical trial program designed to evaluate the combination of Actimab-A with PD-1 inhibitors in treating solid tumors. The rationale behind this program lies in tackling an emerging challenge in cancer treatment: Myeloid-Derived Suppressor Cells (MDSCs), which accumulate in the tumor microenvironment, are known to reduce the effectiveness of PD-1 inhibitors like KEYTRUDA® and OPDIVO®. Actimab-A selectively targets and depletes CD33-expressing MDSCs, a novel mechanism that could enhance the efficacy of PD-1 therapies. If successful, this approach could open the door to a massive market in immuno-oncology with significant growth potential. The Competitive Advantage Actinium Pharmaceuticals, Inc. is working to establish itself as a key player in next-generation radiotherapy, backed by a strong intellectual property portfolio and a growing pipeline of targeted therapies. The company holds 230 patents and patent applications, including critical protections related to the production of Actinium-225 (Ac-225) in a cyclotron—an essential component of its radiotherapy platform. Beyond its intellectual property, Actinium Pharmaceuticals, Inc. is advancing treatments for both hematologic and solid tumors. Its pipeline includes Actimab-A, a targeted radiotherapy designed for acute myeloid leukemia (AML), as well as ongoing research into expanding its use in combination with PD-1 inhibitors for solid tumors. The company is also progressing with its Iomab-B program, which is being developed as an induction and conditioning agent for patients undergoing bone marrow transplants in relapsed or refractory AML. Actinium Pharmaceuticals' Pipeline Grab Sources And More Here: ATNM Website. ----- And based on several potential catalysts, (NYSE American: ATNM) needs watchlist consideration. Check them out: No. 1 ATNM Potential Catalyst - This Week's Breaking News Signals Company Has Access To Reliable And Constant Supply Of Ac-225. Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia (AML) and other myeloid indications. Sandesh Seth, Chairman and CEO at Actium Pharmaceuticals, Inc. commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating patients with myeloid malignancies and solid tumors. As we have highlighted recently, we are advancing our lead targeted radiotherapy Actimab-A into a pivotal Phase 2/3 trial for patients with relapsed or refractory acute myeloid leukemia and in the frontline setting in a Phase 1 trial under our CRADA with the NCI. Additionally, we have launched our Actimab-A solid tumor program to combine with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO for patients with head and neck squamous carcinoma and non-small cell lung cancer in multiple trials. As a pioneer in the development of target radiotherapies, we have aggressive plans to expand our clinical pipeline to address indications with high unmet needs. With this supply agreement with Eckert & Ziegler, we will have access to reliable and constant supply of Ac-225 to advance our product development both in the U.S. as well as internationally."   ...   Read the full article here. -----   No. 2 ATNM Potential Catalyst - A Key Research Collaboration To Expand Actimab-A's Backbone Therapy Strategy.   Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives. The first objective is to study Actimab-A in combination with targeted therapies including FLT3 and menin inhibitors to define transcriptional profiles in AML cells following treatment with these combinations. The second objective is to assess the activity of Actimab-A-based combinations on primary AML patient-derived ex vivo samples from patients with and without prior Venetoclax + hypomethylating agent (HMA) treatment. The collaboration will be done with members of MSKCC's leukemia and early drug development specialist teams. ... Sandesh Seth, Actinium's Chairman and CEO, said, "In 2025 we are reimagining and revitalizing our Actimab-A program leveraging its mutation agnostic, backbone therapy profile. This collaboration with MSKCC will further expand and support novel Actimab-A combinations with targeted therapies like FLT3 and menin inhibitors in AML. As we have demonstrated in combination with CLAG-M, Actimab-A has the potential to improve patients' outcomes via its novel and differentiated mechanism to target radiosensitive AML blasts and produce lethal double strand DNA breaks via the Actinium-225 payload for which there are no known resistance or repair mechanisms. We are eager to execute this collaboration and look forward to generating important data from AML patient derived models. Our goal is to address the unmet needs of over 100,000 patients with myeloid malignancies across the treatment journey with Actimab-A, which represents a multi-Bn-dollar market opp. With recently initiated trials, this exciting research collaboration and clinical data expected in the second half of 2025, we believe we are making great progress to achieve our goal." ...   Read the full article here. -----   No. 3 ATNM Potential Catalyst - Could Support Be Growing At 4 Critical Chart Levels?   ATNM has experienced a remarkable surge since early March, with its valuation soaring over 118% from a low of just above $1.02 to a peak of $2.23+.   This impressive rally has propelled ATNM beyond four crucial technical resistance points on its chart.   Should these newly established levels hold as support, it could potentially sustain ATNM's positive momentum throughout the remainder near term. -----   No. 4 ATNM Potential Catalyst - An Analyst Target May Suggest ATNM To Be Undervalued At Current Levels.   How about triple-digit potential upside?   Stephens, Inc. analyst, Sudan Loganathan, Ph.D., recently shared an "Overweight" rating with a $5.00 target. From its 4:00PM EST closing valuation on Tuesday, ATNM may have over 100% potential upside to this target. -----   (NYSE American: ATNM) Recap - 4 Potential Catalysts To Consider Immediately   No. 1 - This Week's Breaking News Signals Company Has Access To Reliable And Constant Supply Of Ac-225.   No. 2 - A Key Research Collaboration To Expand Actimab-A's Backbone Therapy Strategy.   No. 3 - Could Support Be Growing At 4 Critical Chart Levels?   No. 4 - An Analyst Target May Suggest ATNM To Be Undervalued At Current Levels. -----   Coverage is officially initiated on Actinium Pharmaceuticals, Inc. (NYSE American: ATNM).   When update are available, I'll get them out quickly.   Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com ("StockWireNews" or "SWN" ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/26/2025 and ending on 03/26/2025 to publicly disseminate information about (ATNM:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (ATNM:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/atnm/#details Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States